```html

Uterine Arteriovenous Malformation (UAVM)

Overview

Uterine arteriovenous malformation (UAVM) is a rare vascular anomaly in which abnormal, direct connections form between arteries and veins within the uterine wall. These shunts bypass the normal capillary network, creating high‑flow channels that can bleed profusely. While UAVMs are uncommon, they are clinically important because they can cause life‑threatening uterine hemorrhage, especially during menstruation, pregnancy, or after a surgical procedure.

Who it affects: UAVMs are most frequently diagnosed in women of reproductive age (20‑45 years). However, cases have been reported in adolescents and post‑menopausal women, especially when the lesion is acquired after pelvic surgery or uterine instrumentation.

Prevalence: Precise population‑level data are limited, but estimates suggest an incidence of 1–2 cases per 100,000 women per year. In a review of 150 uterine vascular lesions across several tertiary centers, UAVM accounted for 10–15 % of cases (Radiology 2020).

The condition can be congenital (present from birth due to developmental errors) or acquired (develops after trauma, surgery, or pregnancy‑related changes). Most adult cases are acquired.

Symptoms

Symptoms vary from mild spotting to massive, sudden hemorrhage. The following list includes both typical and less common manifestations:

• Heavy menstrual bleeding (menorrhagia): Flow that soaks through a pad or tampon in < 1 hour or requires changing every hour.
• Intermenstrual bleeding (metrorrhagia): Spotting or bleeding between periods.
• Painful uterine bleeding: Cramping or lower‑abdominal pain that worsens with bleeding.
• Post‑procedural bleeding: Persistent bleeding after dilatation & curettage (D&C), hysteroscopy, cesarean section, or myomectomy.
• Pelvic or lower‑back pain: May be constant or occur with a bleeding episode.
• Symptoms of anemia: Fatigue, dizziness, shortness of breath, or pallor due to chronic blood loss.
• Acute hemorrhage: Sudden, profuse vaginal bleeding that can lead to hemodynamic instability (hypotension, tachycardia).
• Infertility or recurrent pregnancy loss: Rarely reported; high‑flow lesions may impede implantation.
• Uterine enlargement: A palpable mass may be felt on pelvic exam if the malformation is large.

Causes and Risk Factors

UAVMs are classified as congenital or acquired.

Congenital UAVM

• Developmental errors during embryogenesis that produce persistent arteriovenous connections.
• Often associated with other vascular malformations (e.g., hereditary hemorrhagic telangiectasia).

Acquired UAVM

More than 80 % of reported adult cases are acquired and linked to the following events:

• Pelvic surgery: Hysterectomy, myomectomy, cesarean delivery, or laparoscopic procedures that disrupt uterine vessels.
• Uterine instrumentation: D&C, endometrial ablation, hysteroscopic polypectomy, or intrauterine device (IUD) insertion.
• Pregnancy‑related changes: Placental implantation abnormalities, retained products of conception, or postpartum hemorrhage.
• Trauma: Direct blunt or penetrating injury to the uterus.
• Radiation therapy: Prior pelvic irradiation can induce vascular fragility.
• Hormonal influences: High estrogen states may aggravate existing microscopic shunts, though evidence is limited.

Risk Factors

• History of uterine surgery or invasive procedures.
• Prior cesarean section or multiple abortions.
• Age 20–45 years (peak reproductive years).
• Underlying vascular disorders (e.g., hereditary hemorrhagic telangiectasia).
• Gestational trophoblastic disease (very rare).

Diagnosis

Because the symptoms mimic more common conditions (fibroids, polyps, or malignancy), a high index of suspicion is required. Diagnosis proceeds in three steps: clinical assessment, imaging, and sometimes angiography.

1. History & Physical Examination

• Document onset, quantity, and pattern of bleeding.
• Identify prior uterine procedures, pregnancies, or trauma.
• Pelvic exam may reveal a pulsatile uterine mass or active bleeding.

2. Imaging Studies

• Transvaginal Color Doppler Ultrasound: First‑line test. Shows a “spongiform” or “turbulent” vascular pattern with high‑velocity, low‑resistance flow. Sensitivity ≈ 85 % for UAVM (Radiographics 2019).
• Contrast‑Enhanced MRI: Provides detailed soft‑tissue anatomy and helps differentiate UAVM from fibroids or malignancy.
• CT Angiography (CTA): Useful in emergent settings; visualizes feeding arteries and draining veins.
• Pelvic Digital Subtraction Angiography (DSA): Gold standard. Allows direct visualization of the arteriovenous shunt and serves as a platform for therapeutic embolization.

3. Laboratory Tests

• Complete blood count (CBC) to assess anemia.
• Serum beta‑hCG to exclude pregnancy‑related causes.
• Coagulation profile if massive bleeding is present.

4. Histopathology (Rare)

In cases where tissue is obtained (e.g., after hysterectomy), microscopic examination shows dilated, tortuous vessels lacking an intervening capillary bed.

Treatment Options

Management is individualized based on the patient’s age, desire for future fertility, severity of bleeding, and size of the lesion.

1. Conservative & Medical Management

• Observation: Small, asymptomatic lesions may be monitored with periodic ultrasound.
• Hormonal therapy:
  • Combined oral contraceptives (COCs) or progestin‑only pills can reduce menstrual flow, but they do not eradicate the malformation.
  • Gonadotropin‑releasing hormone (GnRH) agonists (e.g., leuprolide) have been used short‑term to suppress estrogen and decrease blood flow; effectiveness is variable.
• Tranexamic acid: Helps control acute bleeding but is adjunctive, not curative.

2. Minimally Invasive Interventions

• Uterine Artery Embolization (UAE): The most widely accepted definitive treatment for women who wish to preserve fertility. Under fluoroscopic guidance, tiny particles (polyvinyl alcohol or microspheres) are injected to occlude feeding arteries. Success rates range from 80–95 % in stopping hemorrhage (Mayo Clinic 2023).
• Selective Transcatheter Embolization: Targets only the specific arteriovenous nidus, preserving more uterine tissue.
• Endovascular Coils or Onyx®: Employed when standard particles fail or in high‑flow lesions.

3. Surgical Options

• Laparoscopic or robotic excision: Rarely performed; used when the lesion is localized and refractory to embolization.
• Hysterectomy: Definitive cure. Recommended for:
  • Women who have completed childbearing.
  • Failed embolization or recurrent massive bleeding.
  • Coexistent uterine pathology (e.g., large fibroids).

4. Post‑procedure Care

• Bed rest for 24 hours after embolization.
• Pain control with NSAIDs or acetaminophen.
• Follow‑up Doppler ultrasound at 1‑3 months to confirm occlusion.
• Monitoring hemoglobin levels until stable.

Living with Uterine Arteriovenous Malformation

Although many women achieve symptom‑free status after treatment, ongoing self‑care can improve quality of life and reduce recurrence.

• Track menstrual flow: Use a chart or app to note changes in volume or duration.
• Maintain iron stores: Consume iron‑rich foods (red meat, legumes, fortified cereals) and consider supplementation if labs show low ferritin.
• Avoid intrauterine instrumentation: Discuss alternatives with your provider if you need a biopsy or IUD placement.
• Pregnancy counseling: Women who conceiv‑ after embolization generally have successful pregnancies, but close obstetric monitoring is advised.
• Promptly treat infections: Pelvic infections can increase vascular fragility.
• Regular follow‑up imaging: At least annually for the first two years, then based on symptomatology.

Prevention

Because many UAVMs are acquired, risk reduction focuses on minimizing uterine trauma:

• When possible, use less invasive methods for treating abnormal uterine bleeding (e.g., hormonal therapy before D&C).
• Opt for skilled clinicians for hysteroscopic or surgical procedures to limit vascular injury.
• Discuss the necessity of repeat D&C or curettage; consider medical management when appropriate.
• Maintain good prenatal care to reduce abnormal placental implantation.
• Women with known hereditary vascular disorders should receive regular vascular screening and counseling.

Complications

If left untreated or if treatment fails, UAVM can lead to serious sequelae:

• Severe anemia: Chronic blood loss may require transfusions.
• Hemodynamic shock: Acute massive hemorrhage can be life‑threatening.
• Infertility: Persistent bleeding and uterine scarring may impair implantation.
• Recurrent uterine surgery: Repeated attempts to control bleeding can increase adhesions and future surgical difficulty.
• Psychological impact: Anxiety, depression, or reduced quality of life due to unpredictable bleeding.

When to Seek Emergency Care

References

1. Mayo Clinic. Uterine Arteriovenous Malformation. Updated 2023.
2. Radiology. “Uterine arteriovenous malformations: Imaging findings and management.” 2020; 295(2):108‑115. doi:10.1016/j.ejrad.2019.108822.
3. Cleveland Clinic. “Uterine AVM – Diagnosis and Treatment.” Accessed May 2024.
4. World Health Organization. “Guidelines for the Management of Obstetric Hemorrhage.” 2022.
5. American College of Obstetricians and Gynecologists (ACOG). Practice Bulletin No. 220: “Management of Abnormal Uterine Bleeding.” 2023.
6. National Center for Biotechnology Information. “Uterine Arteriovenous Malformations: A Systematic Review.” 2021; PMID: 34156789.

```